Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right.
If you have questions about MD Anderson’s appointment process, our
information page may be the best place to start.
Find information and resources for current and returning patients.
Learn about clinical trials at MD Anderson and search our database for open studies.
The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.
Your gift will help support our mission to end cancer and make a difference in the lives of our patients.
Our personalized portal helps you refer your patients and communicate with their MD Anderson care team.
As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.
Choose from 12 allied health programs at School of Health Professions.
Learn about our graduate medical education residency and fellowship opportunities.
The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies.
Journal of Neuro-Oncology
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF
Molecular Cancer Therapeutics
Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma
Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF
Investigational New Drugs
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D
Clinical Cancer Research
Antiangiogenic therapy for glioblastoma: current status and future prospects
Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M
Molecular subtypes of glioblastoma are relevant to lower grade glioma
Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS
Journal of Clinical Oncology
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma
Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept
Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF
Moving toward molecular classification of diffuse gliomas in adults
Theeler BJ, Yung WK, Fuller GN, De Groot JF
High-dose antiangiogenic therapy for glioblastoma: less may be more?
de Groot JF
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma
de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV
Journal of the National Comprehensive Cancer Network
Multigene sets for clinical application in glioma
de Groot JF, Sulman EP, Aldape KD
Clinical trial end points for high-grade glioma: the evolving landscape
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
Lucio-Eterovic AK, Piao Y, de Groot JF
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Milano V, Piao Y, LaFortune T, de Groot J